Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Eugene S. Swenson, M.D., Ph.D.
Alexion Pharmaceuticals, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
56 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Adelaide, Australia
- Research Site
Concord, Australia
- Research Site
Parkville, Australia
- Research Site
Parkville, Australia
- Research Site
Graz, Austria
- Research Site
Innsbruck, Austria
- Research Site
Vienna, Austria
- Research Site
Toronto, Ontario, Canada
- Research Site
Prague, Czechia
- Research Site
Århus N, Denmark
- Research Site
Bron, France
- Research Site
Paris, France
- Research Site
Hamburg, Germany
- Research Site
Heidelberg, Germany
- Research Site
Leipzig, Germany
- Research Site
Hong Kong, Hong Kong
- Research Site
Budapest, Hungary
- Research Site
Jerusalem, Israel
- Research Site
Ramat Gan, Israel
- Research Site
Chiba, Japan
- Research Site
Kumamoto, Japan
- Research Site
Kurume-shi, Japan
- Research Site
Matsuyama, Japan
- Research Site
Meguro-ku, Japan
- Research Site
Sapporo, Japan
- Research Site
Takatsuki-shi, Japan
- Research Site
Yokohama, Japan
- Research Site
Grafton, New Zealand
- Research Site
Warsaw, Poland
- Research Site
Warsaw, Poland
- Research Site
Moscow, Russia
- Research Site
Moscow, Russia
- Research Site
Moscow, Russia
- Research Site
Nizhny Novgorod, Russia
- Research Site
Saint Petersburg, Russia
- Research Site
Belgrade, Serbia
- Research Site
Singapore, Singapore
- Research Site
Daegu, South Korea
- Research Site
Barcelona, Spain
- Research Site
Málaga, Spain
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Feb 2018
- Primary completion
- 30 Jun 2023
- Completion
- 30 Jun 2023
- Last update posted
- 17 Jun 2024
- Registered enrollment
- 214
- Registry id
- NCT03403205
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.